Stem definition | Drug id | CAS RN |
---|---|---|
androgens/anabolic steroids | 2607 | 58-22-0 |
Dose | Unit | Route |
---|---|---|
0.12 | g | O |
18 | mg | P |
0.12 | g | R |
60 | mg | SL |
50 | mg | TD |
3 | mg | TD |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.02 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.97 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 4 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.35 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 24.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.06 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.17 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 13, 1972 | FDA | ACTIENT PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Blood testosterone increased | 262.82 | 22.43 | 36 | 2711 | 117 | 46683198 |
Accidental exposure to product | 243.18 | 22.43 | 77 | 2670 | 21004 | 46662311 |
Expulsion of medication | 145.05 | 22.43 | 17 | 2730 | 4 | 46683311 |
Virilism | 135.89 | 22.43 | 17 | 2730 | 19 | 46683296 |
Precocious puberty | 119.70 | 22.43 | 19 | 2728 | 200 | 46683115 |
Enlarged clitoris | 118.53 | 22.43 | 18 | 2729 | 138 | 46683177 |
Hair growth abnormal | 113.40 | 22.43 | 27 | 2720 | 2531 | 46680784 |
Accidental exposure to product by child | 61.09 | 22.43 | 14 | 2733 | 1109 | 46682206 |
Off label use | 59.99 | 22.43 | 91 | 2656 | 379750 | 46303565 |
Renal infarct | 44.38 | 22.43 | 11 | 2736 | 1216 | 46682099 |
Metaplasia | 42.92 | 22.43 | 9 | 2738 | 471 | 46682844 |
Skin laceration | 42.31 | 22.43 | 21 | 2726 | 18481 | 46664834 |
Hirsutism | 41.49 | 22.43 | 10 | 2737 | 984 | 46682331 |
Atherosclerotic plaque rupture | 41.36 | 22.43 | 5 | 2742 | 3 | 46683312 |
Infertility | 40.31 | 22.43 | 9 | 2738 | 633 | 46682682 |
Borderline serous tumour of ovary | 37.89 | 22.43 | 5 | 2742 | 11 | 46683304 |
Blood testosterone decreased | 31.12 | 22.43 | 5 | 2742 | 57 | 46683258 |
Vaginal disorder | 29.17 | 22.43 | 7 | 2740 | 676 | 46682639 |
Chorioretinopathy | 28.60 | 22.43 | 7 | 2740 | 734 | 46682581 |
Acne | 27.03 | 22.43 | 16 | 2731 | 19903 | 46663412 |
Apocrine breast carcinoma | 26.22 | 22.43 | 3 | 2744 | 0 | 46683315 |
Breast cancer | 24.99 | 22.43 | 21 | 2726 | 45497 | 46637818 |
Focal segmental glomerulosclerosis | 24.09 | 22.43 | 7 | 2740 | 1414 | 46681901 |
Adnexal torsion | 24.08 | 22.43 | 5 | 2742 | 249 | 46683066 |
Libido increased | 23.35 | 22.43 | 6 | 2741 | 766 | 46682549 |
Exposure via skin contact | 23.30 | 22.43 | 4 | 2743 | 70 | 46683245 |
Osteonecrosis | 23.27 | 22.43 | 16 | 2731 | 25728 | 46657587 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Blood testosterone decreased | 1397.41 | 11.56 | 394 | 28569 | 4002 | 29919513 |
Blood testosterone increased | 465.60 | 11.56 | 122 | 28841 | 910 | 29922605 |
Polycythaemia | 269.37 | 11.56 | 90 | 28873 | 1662 | 29921853 |
Application site rash | 239.29 | 11.56 | 69 | 28894 | 760 | 29922755 |
Product administered at inappropriate site | 235.61 | 11.56 | 80 | 28883 | 1555 | 29921960 |
Deep vein thrombosis | 196.09 | 11.56 | 266 | 28697 | 60235 | 29863280 |
Expulsion of medication | 177.89 | 11.56 | 32 | 28931 | 15 | 29923500 |
Product deposit | 177.57 | 11.56 | 43 | 28920 | 222 | 29923293 |
Blood testosterone abnormal | 173.57 | 11.56 | 42 | 28921 | 216 | 29923299 |
Incorrect dose administered | 159.19 | 11.56 | 174 | 28789 | 31512 | 29892003 |
Haematocrit increased | 144.05 | 11.56 | 56 | 28907 | 1620 | 29921895 |
Application site pain | 133.90 | 11.56 | 53 | 28910 | 1610 | 29921905 |
Pulmonary embolism | 126.44 | 11.56 | 251 | 28712 | 77884 | 29845631 |
Precocious puberty | 117.81 | 11.56 | 26 | 28937 | 81 | 29923434 |
Implant site pain | 117.11 | 11.56 | 27 | 28936 | 108 | 29923407 |
Prescribed overdose | 114.41 | 11.56 | 82 | 28881 | 8479 | 29915036 |
Application site erythema | 114.10 | 11.56 | 52 | 28911 | 2251 | 29921264 |
Testicular atrophy | 96.71 | 11.56 | 31 | 28932 | 499 | 29923016 |
Infertility male | 86.88 | 11.56 | 23 | 28940 | 179 | 29923336 |
Toxicity to various agents | 85.98 | 11.56 | 32 | 28931 | 177151 | 29746364 |
Application site pruritus | 83.90 | 11.56 | 36 | 28927 | 1347 | 29922168 |
Insulin-like growth factor increased | 83.19 | 11.56 | 33 | 28930 | 1008 | 29922507 |
Libido decreased | 83.17 | 11.56 | 53 | 28910 | 4513 | 29919002 |
Product quality issue | 80.48 | 11.56 | 95 | 28868 | 18679 | 29904836 |
Death | 75.29 | 11.56 | 145 | 28818 | 357138 | 29566377 |
Product odour abnormal | 73.46 | 11.56 | 26 | 28937 | 574 | 29922941 |
Application site reaction | 73.01 | 11.56 | 24 | 28939 | 420 | 29923095 |
Pituitary tumour benign | 68.46 | 11.56 | 27 | 28936 | 812 | 29922703 |
Gynaecomastia | 64.47 | 11.56 | 58 | 28905 | 8293 | 29915222 |
Craniopharyngioma | 64.32 | 11.56 | 20 | 28943 | 290 | 29923225 |
Blood testosterone free decreased | 63.72 | 11.56 | 15 | 28948 | 67 | 29923448 |
Hypogonadism | 60.86 | 11.56 | 29 | 28934 | 1390 | 29922125 |
Erectile dysfunction | 60.67 | 11.56 | 81 | 28882 | 18021 | 29905494 |
Prostatic specific antigen increased | 60.37 | 11.56 | 66 | 28897 | 11938 | 29911577 |
Febrile neutropenia | 59.38 | 11.56 | 15 | 28948 | 106678 | 29816837 |
Application site exfoliation | 57.93 | 11.56 | 15 | 28948 | 106 | 29923409 |
Oestradiol increased | 55.75 | 11.56 | 12 | 28951 | 32 | 29923483 |
Application site irritation | 54.76 | 11.56 | 22 | 28941 | 695 | 29922820 |
Neutropenia | 54.72 | 11.56 | 28 | 28935 | 128512 | 29795003 |
Azoospermia | 54.39 | 11.56 | 19 | 28944 | 403 | 29923112 |
Hair growth abnormal | 53.51 | 11.56 | 21 | 28942 | 623 | 29922892 |
Application site dryness | 52.66 | 11.56 | 12 | 28951 | 45 | 29923470 |
Secondary hypogonadism | 52.22 | 11.56 | 17 | 28946 | 288 | 29923227 |
Device expulsion | 51.34 | 11.56 | 13 | 28950 | 83 | 29923432 |
Performance enhancing product use | 49.70 | 11.56 | 13 | 28950 | 96 | 29923419 |
Osteonecrosis | 49.23 | 11.56 | 69 | 28894 | 16066 | 29907449 |
Haemoglobin increased | 48.71 | 11.56 | 32 | 28931 | 2870 | 29920645 |
Completed suicide | 48.14 | 11.56 | 18 | 28945 | 99474 | 29824041 |
Application site vesicles | 48.09 | 11.56 | 19 | 28944 | 574 | 29922941 |
Feeling abnormal | 48.01 | 11.56 | 142 | 28821 | 56614 | 29866901 |
Poor quality product administered | 47.89 | 11.56 | 26 | 28937 | 1643 | 29921872 |
Thrombocytopenia | 47.21 | 11.56 | 38 | 28925 | 137006 | 29786509 |
General physical health deterioration | 46.84 | 11.56 | 19 | 28944 | 99925 | 29823590 |
Muscle mass | 46.31 | 11.56 | 15 | 28948 | 250 | 29923265 |
Clear cell renal cell carcinoma | 46.05 | 11.56 | 21 | 28942 | 910 | 29922605 |
Red blood cell count increased | 45.90 | 11.56 | 24 | 28939 | 1405 | 29922110 |
Focal segmental glomerulosclerosis | 45.69 | 11.56 | 26 | 28937 | 1801 | 29921714 |
Implant site bruising | 45.00 | 11.56 | 8 | 28955 | 3 | 29923512 |
Drug ineffective | 44.85 | 11.56 | 514 | 28449 | 339873 | 29583642 |
Hyperoestrogenism | 43.66 | 11.56 | 8 | 28955 | 5 | 29923510 |
Implant site infection | 42.96 | 11.56 | 20 | 28943 | 909 | 29922606 |
Pyrexia | 42.92 | 11.56 | 144 | 28819 | 294345 | 29629170 |
Sleep apnoea syndrome | 41.25 | 11.56 | 65 | 28898 | 16792 | 29906723 |
Wrong technique in product usage process | 40.90 | 11.56 | 92 | 28871 | 31063 | 29892452 |
Acute myocardial infarction | 40.60 | 11.56 | 128 | 28835 | 52811 | 29870704 |
Prostate cancer | 39.91 | 11.56 | 78 | 28885 | 23879 | 29899636 |
Cerebrovascular accident | 38.99 | 11.56 | 172 | 28791 | 83305 | 29840210 |
Insulin-like growth factor decreased | 38.16 | 11.56 | 13 | 28950 | 255 | 29923260 |
Infertility | 37.97 | 11.56 | 12 | 28951 | 184 | 29923331 |
Thrombosis | 36.98 | 11.56 | 107 | 28856 | 42124 | 29881391 |
Drug abuse | 36.74 | 11.56 | 167 | 28796 | 81905 | 29841610 |
Application site discolouration | 36.29 | 11.56 | 12 | 28951 | 214 | 29923301 |
Acne | 35.95 | 11.56 | 45 | 28918 | 9391 | 29914124 |
Anaemia | 35.06 | 11.56 | 95 | 28868 | 207897 | 29715618 |
Acute kidney injury | 34.57 | 11.56 | 142 | 28821 | 273700 | 29649815 |
Drug interaction | 34.51 | 11.56 | 90 | 28873 | 199478 | 29724037 |
Application site urticaria | 33.89 | 11.56 | 9 | 28954 | 71 | 29923444 |
Mesenteric vein thrombosis | 32.92 | 11.56 | 14 | 28949 | 512 | 29923003 |
Blood oestrogen increased | 32.92 | 11.56 | 8 | 28955 | 42 | 29923473 |
Product container issue | 32.69 | 11.56 | 16 | 28947 | 814 | 29922701 |
Myocardial infarction | 32.31 | 11.56 | 220 | 28743 | 125405 | 29798110 |
Drug-disease interaction | 31.07 | 11.56 | 11 | 28952 | 243 | 29923272 |
Blood testosterone free increased | 29.78 | 11.56 | 6 | 28957 | 10 | 29923505 |
Virilism | 29.71 | 11.56 | 5 | 28958 | 0 | 29923515 |
Product administration error | 29.22 | 11.56 | 51 | 28912 | 14326 | 29909189 |
Interstitial lung disease | 28.92 | 11.56 | 11 | 28952 | 60186 | 29863329 |
Product physical consistency issue | 28.83 | 11.56 | 11 | 28952 | 302 | 29923213 |
Pancytopenia | 28.74 | 11.56 | 24 | 28939 | 85028 | 29838487 |
Sepsis | 28.48 | 11.56 | 62 | 28901 | 146333 | 29777182 |
Headache | 28.40 | 11.56 | 285 | 28678 | 182021 | 29741494 |
Product dose omission issue | 28.20 | 11.56 | 168 | 28795 | 91463 | 29832052 |
Lymphoproliferative disorder | 28.14 | 11.56 | 21 | 28942 | 2309 | 29921206 |
Implant site haemorrhage | 27.91 | 11.56 | 8 | 28955 | 86 | 29923429 |
Breast cancer | 27.76 | 11.56 | 11 | 28952 | 335 | 29923180 |
Implant site swelling | 27.19 | 11.56 | 8 | 28955 | 95 | 29923420 |
Product physical issue | 27.16 | 11.56 | 20 | 28943 | 2154 | 29921361 |
Septic shock | 26.82 | 11.56 | 14 | 28949 | 63593 | 29859922 |
Pneumonia | 26.54 | 11.56 | 202 | 28761 | 334104 | 29589411 |
Malignant neoplasm progression | 26.19 | 11.56 | 19 | 28944 | 72268 | 29851247 |
Depression | 26.05 | 11.56 | 163 | 28800 | 90274 | 29833241 |
Coronary artery disease | 25.95 | 11.56 | 106 | 28857 | 49606 | 29873909 |
Myocardial fibrosis | 25.73 | 11.56 | 13 | 28950 | 708 | 29922807 |
Left ventricular hypertrophy | 25.63 | 11.56 | 31 | 28932 | 6247 | 29917268 |
Hyperhidrosis | 25.31 | 11.56 | 130 | 28833 | 66960 | 29856555 |
Stubbornness | 25.10 | 11.56 | 6 | 28957 | 29 | 29923486 |
Pituitary tumour recurrent | 25.06 | 11.56 | 7 | 28956 | 68 | 29923447 |
Muscle hypertrophy | 24.93 | 11.56 | 6 | 28957 | 30 | 29923485 |
Anger | 24.64 | 11.56 | 41 | 28922 | 11079 | 29912436 |
Product storage error | 23.59 | 11.56 | 30 | 28933 | 6361 | 29917154 |
Application site dermatitis | 23.34 | 11.56 | 6 | 28957 | 41 | 29923474 |
Fatigue | 23.30 | 11.56 | 437 | 28526 | 320236 | 29603279 |
Hypogonadism male | 23.19 | 11.56 | 9 | 28954 | 259 | 29923256 |
Renal failure | 23.16 | 11.56 | 57 | 28906 | 128909 | 29794606 |
Acne fulminans | 23.06 | 11.56 | 8 | 28955 | 166 | 29923349 |
Neoplasm recurrence | 22.93 | 11.56 | 17 | 28946 | 1850 | 29921665 |
Insulin resistance | 22.63 | 11.56 | 11 | 28952 | 551 | 29922964 |
Cholelithiasis | 22.49 | 11.56 | 56 | 28907 | 20169 | 29903346 |
Blood follicle stimulating hormone decreased | 22.30 | 11.56 | 6 | 28957 | 50 | 29923465 |
Blood luteinising hormone decreased | 21.70 | 11.56 | 7 | 28956 | 115 | 29923400 |
Hypotension | 21.69 | 11.56 | 110 | 28853 | 200455 | 29723060 |
Loss of libido | 21.58 | 11.56 | 17 | 28946 | 2025 | 29921490 |
Melaena | 21.34 | 11.56 | 3 | 28960 | 32434 | 29891081 |
Stomatitis | 21.19 | 11.56 | 5 | 28958 | 37274 | 29886241 |
Injection site pain | 21.16 | 11.56 | 71 | 28892 | 30239 | 29893276 |
Treatment failure | 21.04 | 11.56 | 4 | 28959 | 34675 | 29888840 |
Intentional overdose | 20.91 | 11.56 | 7 | 28956 | 41474 | 29882041 |
Hypercoagulation | 20.88 | 11.56 | 13 | 28950 | 1062 | 29922453 |
Pituitary tumour | 20.80 | 11.56 | 10 | 28953 | 489 | 29923026 |
Hormone level abnormal | 20.79 | 11.56 | 9 | 28954 | 344 | 29923171 |
Decreased appetite | 20.62 | 11.56 | 75 | 28888 | 149835 | 29773680 |
Renal infarct | 20.30 | 11.56 | 13 | 28950 | 1116 | 29922399 |
Implant site erythema | 20.18 | 11.56 | 6 | 28957 | 74 | 29923441 |
Multiple organ dysfunction syndrome | 20.14 | 11.56 | 19 | 28944 | 63468 | 29860047 |
Application site paraesthesia | 20.11 | 11.56 | 4 | 28959 | 6 | 29923509 |
Glucose tolerance decreased | 19.97 | 11.56 | 6 | 28957 | 77 | 29923438 |
Therapeutic response unexpected | 19.96 | 11.56 | 33 | 28930 | 8870 | 29914645 |
Breast tenderness | 19.89 | 11.56 | 11 | 28952 | 721 | 29922794 |
Platelet count decreased | 19.77 | 11.56 | 46 | 28917 | 106083 | 29817432 |
Chorioretinopathy | 19.60 | 11.56 | 14 | 28949 | 1438 | 29922077 |
Cardio-respiratory arrest | 19.56 | 11.56 | 16 | 28947 | 57290 | 29866225 |
Oligospermia | 19.55 | 11.56 | 6 | 28957 | 83 | 29923432 |
Product complaint | 19.47 | 11.56 | 26 | 28937 | 5780 | 29917735 |
Accidental exposure to product | 19.41 | 11.56 | 35 | 28928 | 10080 | 29913435 |
Skin irritation | 19.27 | 11.56 | 22 | 28941 | 4170 | 29919345 |
Cardiac death | 18.83 | 11.56 | 12 | 28951 | 1021 | 29922494 |
Leukopenia | 18.78 | 11.56 | 16 | 28947 | 56143 | 29867372 |
Implant site mass | 18.77 | 11.56 | 4 | 28959 | 10 | 29923505 |
Factor V Leiden mutation | 18.49 | 11.56 | 4 | 28959 | 11 | 29923504 |
Transient ischaemic attack | 18.46 | 11.56 | 60 | 28903 | 25140 | 29898375 |
Expired product administered | 18.44 | 11.56 | 18 | 28945 | 2851 | 29920664 |
Cardiac failure | 18.21 | 11.56 | 33 | 28930 | 83385 | 29840130 |
Confusional state | 18.18 | 11.56 | 68 | 28895 | 134766 | 29788749 |
Blood growth hormone increased | 18.12 | 11.56 | 7 | 28956 | 199 | 29923316 |
Application site inflammation | 17.94 | 11.56 | 6 | 28957 | 111 | 29923404 |
Acromegaly | 17.86 | 11.56 | 5 | 28958 | 49 | 29923466 |
Angiofibroma | 17.83 | 11.56 | 3 | 28960 | 0 | 29923515 |
C-reactive protein increased | 17.70 | 11.56 | 10 | 28953 | 43463 | 29880052 |
Growth hormone-producing pituitary tumour | 17.55 | 11.56 | 4 | 28959 | 15 | 29923500 |
Prostatomegaly | 17.49 | 11.56 | 22 | 28941 | 4614 | 29918901 |
Needle issue | 17.43 | 11.56 | 20 | 28943 | 3812 | 29919703 |
Spinal cord abscess | 17.40 | 11.56 | 7 | 28956 | 222 | 29923293 |
Portal vein thrombosis | 17.33 | 11.56 | 19 | 28944 | 3445 | 29920070 |
Thyroxine decreased | 17.32 | 11.56 | 6 | 28957 | 124 | 29923391 |
Acne conglobata | 17.15 | 11.56 | 4 | 28959 | 17 | 29923498 |
Growth accelerated | 17.15 | 11.56 | 4 | 28959 | 17 | 29923498 |
Amnesia | 17.00 | 11.56 | 57 | 28906 | 24264 | 29899251 |
Obesity | 16.93 | 11.56 | 30 | 28933 | 8525 | 29914990 |
Bone marrow failure | 16.92 | 11.56 | 4 | 28959 | 29781 | 29893734 |
Application site burn | 16.67 | 11.56 | 7 | 28956 | 248 | 29923267 |
Gastrointestinal haemorrhage | 16.49 | 11.56 | 35 | 28928 | 83411 | 29840104 |
Disease progression | 16.21 | 11.56 | 33 | 28930 | 79841 | 29843674 |
Cerebral venous thrombosis | 16.16 | 11.56 | 9 | 28954 | 598 | 29922917 |
Underdose | 16.09 | 11.56 | 36 | 28927 | 12105 | 29911410 |
Bradycardia | 16.09 | 11.56 | 24 | 28939 | 65502 | 29858013 |
Circumstance or information capable of leading to medication error | 16.09 | 11.56 | 13 | 28950 | 1606 | 29921909 |
Aortic aneurysm | 16.06 | 11.56 | 25 | 28938 | 6388 | 29917127 |
Anorgasmia | 16.05 | 11.56 | 9 | 28954 | 606 | 29922909 |
Liquid product physical issue | 15.92 | 11.56 | 7 | 28956 | 278 | 29923237 |
Implant site cellulitis | 15.87 | 11.56 | 4 | 28959 | 25 | 29923490 |
Implant site necrosis | 15.75 | 11.56 | 3 | 28960 | 3 | 29923512 |
Dermal absorption impaired | 15.75 | 11.56 | 3 | 28960 | 3 | 29923512 |
Mucosal inflammation | 15.62 | 11.56 | 5 | 28958 | 30489 | 29893026 |
Stress | 15.56 | 11.56 | 49 | 28914 | 20186 | 29903329 |
Penis disorder | 15.48 | 11.56 | 11 | 28952 | 1121 | 29922394 |
Hyperkalaemia | 15.42 | 11.56 | 25 | 28938 | 65985 | 29857530 |
Testis discomfort | 15.29 | 11.56 | 3 | 28960 | 4 | 29923511 |
Sperm concentration zero | 15.29 | 11.56 | 3 | 28960 | 4 | 29923511 |
Testicular pain | 15.27 | 11.56 | 16 | 28947 | 2756 | 29920759 |
Blood thyroid stimulating hormone decreased | 14.72 | 11.56 | 13 | 28950 | 1814 | 29921701 |
Retinal vein occlusion | 14.40 | 11.56 | 12 | 28951 | 1547 | 29921968 |
Irritability | 14.36 | 11.56 | 52 | 28911 | 22998 | 29900517 |
Intentional product misuse | 14.36 | 11.56 | 69 | 28894 | 34598 | 29888917 |
Hepatic adenoma | 14.31 | 11.56 | 4 | 28959 | 39 | 29923476 |
Congestive cardiomyopathy | 14.11 | 11.56 | 24 | 28939 | 6603 | 29916912 |
Thrombophlebitis superficial | 13.98 | 11.56 | 15 | 28948 | 2654 | 29920861 |
Ophthalmic vein thrombosis | 13.96 | 11.56 | 4 | 28959 | 43 | 29923472 |
Orchidectomy | 13.63 | 11.56 | 4 | 28959 | 47 | 29923468 |
Empty sella syndrome | 13.48 | 11.56 | 4 | 28959 | 49 | 29923466 |
Drug withdrawal syndrome | 13.47 | 11.56 | 46 | 28917 | 19763 | 29903752 |
Nipple pain | 13.31 | 11.56 | 8 | 28955 | 614 | 29922901 |
Dehydration | 13.19 | 11.56 | 68 | 28895 | 123471 | 29800044 |
Neutrophil count decreased | 13.12 | 11.56 | 13 | 28950 | 42441 | 29881074 |
Eye colour change | 13.03 | 11.56 | 6 | 28957 | 266 | 29923249 |
Skin odour abnormal | 12.92 | 11.56 | 9 | 28954 | 888 | 29922627 |
Sperm concentration decreased | 12.91 | 11.56 | 5 | 28958 | 143 | 29923372 |
Mood swings | 12.90 | 11.56 | 25 | 28938 | 7601 | 29915914 |
Thyrotoxic periodic paralysis | 12.68 | 11.56 | 4 | 28959 | 61 | 29923454 |
Gastric hypomotility | 12.56 | 11.56 | 4 | 28959 | 63 | 29923452 |
Device extrusion | 12.47 | 11.56 | 3 | 28960 | 15 | 29923500 |
Drug reaction with eosinophilia and systemic symptoms | 12.41 | 11.56 | 6 | 28957 | 28482 | 29895033 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 12.26 | 11.56 | 9 | 28954 | 965 | 29922550 |
Pollakiuria | 12.15 | 11.56 | 40 | 28923 | 16866 | 29906649 |
Astrocytoma | 11.96 | 11.56 | 5 | 28958 | 175 | 29923340 |
Dyspnoea | 11.95 | 11.56 | 239 | 28724 | 333056 | 29590459 |
Cardiomyopathy | 11.95 | 11.56 | 37 | 28926 | 15106 | 29908409 |
Autoimmune thyroiditis | 11.89 | 11.56 | 9 | 28954 | 1011 | 29922504 |
Diarrhoea | 11.85 | 11.56 | 240 | 28723 | 333863 | 29589652 |
Cardiac arrest | 11.76 | 11.56 | 48 | 28915 | 92802 | 29830713 |
Penile size reduced | 11.73 | 11.56 | 5 | 28958 | 184 | 29923331 |
Carotid artery occlusion | 11.72 | 11.56 | 12 | 28951 | 2013 | 29921502 |
Gamma-glutamyltransferase increased | 11.59 | 11.56 | 7 | 28956 | 29343 | 29894172 |
Oxygen saturation decreased | 11.57 | 11.56 | 15 | 28948 | 43425 | 29880090 |
Source | Code | Description |
---|---|---|
ATC | G03BA03 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS 3-oxoandrosten (4) derivatives |
ATC | G03EA02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION Androgens and estrogens |
FDA CS | M0001109 | Androstanes |
FDA MoA | N0000000146 | Androgen Receptor Agonists |
FDA EPC | N0000175824 | Androgen |
MeSH PA | D000728 | Androgens |
MeSH PA | D006728 | Hormones |
CHEBI has role | CHEBI:50113 | androgens |
CHEBI has role | CHEBI:75771 | mus musculus metabolite |
CHEBI has role | CHEBI:77746 | h. sapiens metabolites |
CHEBI has role | CHEBI:83056 | daphnia magna metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypogonadotropic hypogonadism | indication | 33927004 | |
Deficiency of testosterone biosynthesis | indication | 38825009 | |
Inhibition of lactation procedure | indication | 43141007 | |
Male hypogonadism | indication | 48723006 | |
Hypopituitarism | indication | 74728003 | DOID:9406 |
Menopausal flushing | indication | 198436008 | |
Undescended testicle | indication | 204878001 | DOID:11383 |
Bilateral orchidectomy | indication | 386634006 | |
Delayed puberty | indication | 400003000 | |
Klinefelter's syndrome, XXY | indication | 405769009 | |
Hormone receptor positive malignant neoplasm of breast | indication | 417181009 | |
Primary Hypogonadism due to Bilateral Torsion | indication | ||
Primary Hypogonadism due to Orchitis | indication | ||
LHRH Deficiency | indication | ||
Chemotherapy-Induced Hypogonadism | indication | ||
Bilateral Anorchia | indication | ||
Noonan's syndrome | off-label use | 205824006 | DOID:3490 |
Hyperlipoproteinemia | contraindication | 3744001 | DOID:1168 |
Gynecomastia | contraindication | 4754008 | DOID:12698 |
Hypocalcemia | contraindication | 5291005 | |
Hypercholesterolemia | contraindication | 13644009 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Chloasma | contraindication | 36209000 | |
Migraine | contraindication | 37796009 | DOID:6364 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Body fluid retention | contraindication | 43498006 | |
Thrombosis of retinal vein | contraindication | 46085004 | |
Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
Chronic heart failure | contraindication | 48447003 | |
Dementia | contraindication | 52448006 | |
Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Heart disease | contraindication | 56265001 | DOID:114 |
Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
Intermenstrual bleeding - irregular | contraindication | 64996003 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Arteriosclerotic vascular disease | contraindication | 72092001 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Sleep apnea | contraindication | 73430006 | DOID:0050847 |
Heart failure | contraindication | 84114007 | DOID:6000 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Breast lump | contraindication | 89164003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
Magnetic resonance imaging | contraindication | 113091000 | |
Neoplasm of liver | contraindication | 126851005 | DOID:3571 |
Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
Deep venous thrombosis | contraindication | 128053003 | |
Endometriosis | contraindication | 129103003 | |
Mammography abnormal | contraindication | 168750009 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Cerebrovascular accident | contraindication | 230690007 | |
Pulmonary thromboembolism | contraindication | 233935004 | |
Thrombophilia | contraindication | 234467004 | DOID:2452 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Edema | contraindication | 267038008 | |
Chorea | contraindication | 271700006 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Functional visual loss | contraindication | 313165001 | |
Malignant tumor of ovary | contraindication | 363443007 | DOID:2394 |
Thromboembolic disorder | contraindication | 371039008 | |
Cardiovascular event risk | contraindication | 395112001 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Chronic lung disease | contraindication | 413839001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Estrogen receptor positive tumor | contraindication | 416053008 | |
Family history of malignant neoplasm of breast | contraindication | 429740004 | |
Hypertensive urgency | contraindication | 443482000 | |
Carcinoma of female breast | contraindication | 447782002 | |
Smokes tobacco daily | contraindication | 449868002 | |
Breast Carcinoma in Males | contraindication |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Androgen receptor | Nuclear hormone receptor | AGONIST | EC50 | 9.20 | WOMBAT-PK | CHEMBL | |||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 5.84 | DRUG MATRIX | |||||
Aromatase | Enzyme | Ki | 6.22 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 5.92 | CHEMBL | |||||
Sex hormone-binding globulin | Secreted | Kd | 9.20 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | IC50 | 4.30 | CHEMBL | |||||
Corticosteroid-binding globulin | Secreted | Ki | 6.72 | CHEMBL | |||||
Progesterone receptor | Transcription factor | Ki | 6.60 | DRUG MATRIX | |||||
Steroid 5-alpha-reductase | Enzyme | IC50 | 5.72 | CHEMBL | |||||
Androgen receptor | Transcription factor | Ki | 8.85 | CHEMBL | |||||
Constitutive androstane receptor | Unclassified | IC50 | 4.52 | CHEMBL | |||||
C-8 sterol isomerase | Enzyme | Ki | 5.11 | CHEMBL |
ID | Source |
---|---|
4017484 | VUID |
N0000145872 | NUI |
D00075 | KEGG_DRUG |
4017484 | VANDF |
C0039601 | UMLSCUI |
CHEBI:17347 | CHEBI |
TES | PDB_CHEM_ID |
CHEMBL386630 | ChEMBL_ID |
CHEMBL1201101 | ChEMBL_ID |
D013739 | MESH_DESCRIPTOR_UI |
1900 | INN_ID |
DB00624 | DRUGBANK_ID |
3XMK78S47O | UNII |
6013 | PUBCHEM_CID |
2858 | IUPHAR_LIGAND_ID |
10379 | RXNORM |
2966 | MMSL |
5552 | MMSL |
d00558 | MMSL |
001245 | NDDF |
109033004 | SNOMEDCT_US |
43688007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Androderm | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5990 | PATCH | 2 mg | TRANSDERMAL | NDA | 34 sections |
Androderm | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5992 | PATCH | 4 mg | TRANSDERMAL | NDA | 34 sections |
Androgel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0051-8425 | GEL | 10 mg | TRANSDERMAL | NDA | 30 sections |
Androgel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0051-8450 | GEL | 10 mg | TRANSDERMAL | NDA | 30 sections |
Androgel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0051-8462 | GEL | 16.20 mg | TRANSDERMAL | NDA | 29 sections |
Androgel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0051-8488 | GEL | 10 mg | TRANSDERMAL | NDA | 30 sections |
Vogelxo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0245-0871 | GEL | 50 mg | TOPICAL | NDA | 37 sections |
Vogelxo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0245-0872 | GEL, METERED | 12.50 mg | TOPICAL | NDA | 37 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0254-1012 | GEL | 50 mg | TRANSDERMAL | NDA AUTHORIZED GENERIC | 33 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2114 | SOLUTION | 30 mg | TOPICAL | ANDA | 33 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2363 | GEL, METERED | 10 mg | TOPICAL | ANDA | 33 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2921 | GEL | 10 mg | TOPICAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2924 | GEL | 16.20 mg | TRANSDERMAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2925 | GEL | 16.20 mg | TRANSDERMAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2926 | GEL | 16.20 mg | TRANSDERMAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3216 | GEL | 10 mg | TOPICAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3217 | GEL | 10 mg | TOPICAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3524 | GEL | 50 mg | TRANSDERMAL | ANDA | 30 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-7831 | GEL, METERED | 10 mg | TOPICAL | NDA AUTHORIZED GENERIC | 34 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1120 | GEL | 50 mg | TOPICAL | NDA authorized generic | 35 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1121 | GEL, METERED | 12.50 mg | TOPICAL | NDA authorized generic | 35 sections |
Testim | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-853 | GEL | 50 mg | TOPICAL | NDA | 13 sections |
testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-967 | GEL | 20.25 mg | TOPICAL | ANDA | 33 sections |
testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-968 | GEL | 20.25 mg | TOPICAL | ANDA | 33 sections |
testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-969 | GEL | 40.50 mg | TOPICAL | ANDA | 33 sections |
Androgel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-112 | GEL | 10 mg | TRANSDERMAL | NDA | 18 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-078 | GEL | 16.20 mg | TRANSDERMAL | ANDA | 29 sections |
Natestonasal gel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42667-5511 | GEL, METERED | 5.50 mg | NULLSAL | NDA | 33 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-304 | GEL, METERED | 1.62 mg | TRANSDERMAL | ANDA | 31 sections |
Testopel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43773-1001 | PELLET | 75 mg | SUBCUTANEOUS | ANDA | 12 sections |